Skip to content
DataLookout
Menu

NCT06929663

A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorAkeso
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 7 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Nov 5, 2026 to Jun 30, 2028 Show 6 more changesShow less
    • Enrollment increased: 48 → 166 participants
    • Eligibility criteria expanded, about 22 words
    • Study completion pushed from May 5, 2027 to Dec 30, 2028
    • Interventions modified
    • Trial arms changed: 1 → 3
    • Study title expanded, about 7 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 5, 2025 to Jul 2, 2025
    • Secondary endpoints: details revised at 1 of 8 entries
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of participants with dose limiting toxicities (DLTs)
Timeframe: During the first 3 weeks of treatment.
Number of participants with adverse events (AEs)
Timeframe: From the time of informed consent signed through 90 days after the last dose of study drug

Secondary (8)

Serum PK concentration of AK146D1
Anti-drug antibodies (ADA)
Objective Response Rate (ORR) assessed by investigator per RECIST v1.1
Disease Control Rate (DCR) assessed per RECIST v1.1
Duration of response (DoR) assessed by the investigator per RECIST v1.1
Show 3 moreShow less
Time to response (TTR) assessed by the investigator per RECIST v1.1
Progression Free Survival (PFS) assessed by investigator per RECIST v1.1
Overall survival (OS)

Arms and interventions

AK146D1 for injectionExperimental

AK146D1 for injection will be administered in pre-specified dose levels

AK146D1+AK112Experimental

To use AK146D1+AK112 for the treatment.

AK146D1+AK104Experimental

To use AK146D1+AK104 for the treatment.

Drugs: AK146D1 for injection, AK112 Injection, AK104 injection

Sites

1 site in 1 country

  • Scientia Clinical ResearchSydney, New South Wales, Australia